Compare Enveric Biosciences Inc (ENVB) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Gold Fields Limited — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Gold Fields Limited trades at $36.9 (market cap $31.26B). The key difference: Gold Fields Limited is far larger — about 4672.6× Enveric Biosciences Inc's market cap, and Gold Fields Limited pays a 6.14% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Gold Fields Limited for 49 Days on average.
| ENVB | GFI | |
|---|---|---|
Market Cap | $6.69M | $31.26B |
Volume | 41,141 | 3,397,922 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $61.52 |
52-Week Low | $1.27 | $31.25 |
Typical Hold Time | 14 Days | 49 Days |
Enterprise Value | -$1.60M | $31.87B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Gold Fields (GFI) trades at $35.86, down 0.86% with bearish technical signals but strong fundamentals including 40.76% net margin and 58.38% ROE. Recent earnings show mixed results with one beat and three misses against expectations. The company's proposed $27 billion takeover of Northern Star was rejected, creating near-term uncertainty while highlighting growth ambitions. Operating cash flow surged to $3.77 billion in 2025, supporting robust shareholder returns.
GFI presents a value opportunity with low P/E of 7.14 and 44% upside to consensus target of $52.75, though recent acquisition volatility and earnings misses warrant caution. The stock's bearish technical posture contrasts with strong cash generation and analyst support (8 Buy, 10 Hold ratings), creating potential for recovery as standalone operations deliver growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
